Caroline L Alvares (Caroline Alvares)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Acute Myeloid Leukemia

Tyrosine Kinase

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Melisa Halilovic, Mohamed Abdelsalam, Joanna Zabkiewicz, Michelle Lazenby, Caroline L Alvares, Matthias Schmidt, Walburgis Brenner, Sara Najafi, Ina Oehme, Christoph Hieber, Yanira Zeyn, Matthias Bros, Wolfgang Sippl, Oliver Holger Krämer
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins. Leukemia (2024)
Claudia Chiriches, Nathalie Guillen, Maria Wieske, Heba Elhaddad, Ecmel Mehmetbeyoglu, Caroline L Alvares, Dörte Becher, Paul Hole, Oliver Gerhard Ottmann, Martin Ruthardt
Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation. PLoS genetics 18 (10) (2022)
Gonzalo Carreno-Tarragona, Alberto Alvarez-Larran, Claire N Harrison, Jose Carlos Martínez Ávila, Juan Carlos Carlos Hernández-Boluda, Francisca Ferrer-Marín, Deepti H Radia, Elvira Mora Casterá, Sebastian Francis, Teresa González-Martínez, Kathryn Goddard, Manuel Mateo Pérez Encinas, Srinivasan Narayanan, Jose Maria Raya, Vikram Singh, Peter Toth, Xabier Gutiérrez, Paula Amat Martinez, Louisa McIlwaine, Magda Alobaidi, Karan Mayani, Andrew McGregor, Ruth Stuckey, Bethan Psaila, Adrian Segura, Caroline L Alvares, Kerri Davidson, Santiago Osorio, Robert Cutting, Caroline P Sweeney, Laura Rufian, Laura Moreno, Isabel Cuenca, Jeffrey Smith, Maria Luz Morales, Rodrigo Gil-Manso, Ioannis Koutsavlis, Lihui Wang, Adam J Mead, Maria Rozman, Joaquin Martínez-López, Rosa María Ayala, Nicholas C P Cross
CNL and aCML should be considered as single entity based on molecular profiles and outcomes. Blood advances (2022)
Joanna Zabkiewicz, Michelle Lazenby, Gareth Edwards, Ceri A Bygrave, Nader Omidvar, Lihui Zhuang, Steve Knapper, Carol Guy, Robert K Hills, Alan K Burnett, Caroline L Alvares
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia. British journal of haematology 191 (2) (2020)